Frequency of Factor VIII Inhibitors in a Developing Country; Iran Experiences

Hemophilia A, or classic hemophilia, is an X-linked recessive disorder of coagulation system that usually affects males. It mostly inherits from parents, while about 30% of individuals with hemophilia A inherit it via spontaneous mutations in factor VIII gene. The mainstone of treatment in hemophilia A is replacement therapy with factor VIII concentrates. The major burden appeared in current decade in hemophilia was development of factor VIII inhibitors, that made challenges for both the patients and hematologists. The factor VIII inhibitors have been paid suitably in developed countries. It seems that factor VIII inhibitors in developing countries need more attention to be paid. Here a review on published data on frequency of factor VIII inhibitors in diverse territories of Iran has been presented.